LIN vs SOLV · P/E 34, rev $33.99B vs P/E 9.1, rev $8.25B
Linde plc Ordinary Shares (LIN) versus Solventum Corp. (SOLV) — a side-by-side from cached financials, not a winner call.
Linde plc Ordinary Shares (LIN) is a specialty chemicals company listed on US.
Solventum Corp. (SOLV) is a medical instruments & supplies company listed on NYSE.
Latest reported LIN revenue for 2025-12-31 was $33.99B. Net income was $6.90B. Revenue was up 3.0% from 2024-12-31 to 2025-12-31. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
Latest reported SOLV revenue for 2024-12-31 was $8.25B. Net income was $479.0M. Revenue was up 0.7% from 2023-12-31 to 2024-12-31. SOLV currently screens at market cap $12.91B and trailing P/E 9.1.
LIN currently screens at market cap $223.87B and trailing P/E 34.5. SOLV currently screens at market cap $12.91B and trailing P/E 9.1.
Not investment advice. Open the LIN and SOLV stock pages for the full models.
Not investment advice.